TY - JOUR
T1 - Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis
AU - Taddio, Andrea
AU - Cattalini, Marco
AU - Simonini, Gabriele
AU - Cimaz, Rolando
PY - 2016/2/21
Y1 - 2016/2/21
N2 - Juvenile Idiopathic Arthritis (JIA) encompasses a group of diseases of unknown etiology having in common arthritis in at least 1 joint that persists for 6 weeks and begins before 16 years of age, with other conditions excluded. With a prevalence of 1 per 1,000 children in the USA, JIA is the most common pediatric rheumatic illness and a major cause of acquired childhood disability. During the last 20 years, the advent of host immune response modifiers known as biologic agents, in particular the anti-TNFα agents (etanercept, infliximab, adalimumab), which directly inhibit the action of pro-inflammatory mediators, has revolutionized the treatment and the expected outcome of JIA. This article highlights treatment indications of anti-TNFα drugs and their more frequent side effects in JIA patients.
AB - Juvenile Idiopathic Arthritis (JIA) encompasses a group of diseases of unknown etiology having in common arthritis in at least 1 joint that persists for 6 weeks and begins before 16 years of age, with other conditions excluded. With a prevalence of 1 per 1,000 children in the USA, JIA is the most common pediatric rheumatic illness and a major cause of acquired childhood disability. During the last 20 years, the advent of host immune response modifiers known as biologic agents, in particular the anti-TNFα agents (etanercept, infliximab, adalimumab), which directly inhibit the action of pro-inflammatory mediators, has revolutionized the treatment and the expected outcome of JIA. This article highlights treatment indications of anti-TNFα drugs and their more frequent side effects in JIA patients.
UR - http://www.scopus.com/inward/record.url?scp=84958811496&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958811496&partnerID=8YFLogxK
U2 - 10.1586/1744666X.2016.1146132
DO - 10.1586/1744666X.2016.1146132
M3 - Article
AN - SCOPUS:84958811496
SP - 1
EP - 9
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
SN - 1744-666X
ER -